Avidity Biosciences, Inc. (RNAM)

SEC fundamentals · as filed in 10-K FY2025, period ended Dec 31, 2025 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$1.96B
Stockholders' Equity
$1.69B
Cash & Equivalents
$382.5M
Long-Term Debt
—

as filed in 10-K FY2025, period ended Dec 31, 2025 · View filings on EDGAR ↗

In its 10-K for the period ended Dec 31, 2025, Avidity Biosciences, Inc. reported revenue of $18.8M, net income of -$684.6M, and total assets of $1.96B. Every figure below is taken directly from Avidity Biosciences, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2018–FY2025 · as reported

$18.8M-$332.9M-$684.6M
FY2018FY2020FY2022FY2024FY2025
Revenue$18.8MNet income-$684.6M
FY2018 revenue
$379,000
FY2025 revenue
$18.8M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$18.8M-$684.6M
FY2024$10.9M-$322.3M
FY2023$9.6M-$212.2M
FY2022$9.2M-$174.0M
FY2021$9.3M-$118.0M
FY2020$6.8M-$44.4M
FY2019$2.3M-$24.7M
FY2018$379,000-$11.2M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KFeb 27, 2026on EDGAR ↗
8-KFeb 26, 2026on EDGAR ↗
10-KFeb 23, 2026on EDGAR ↗
8-KFeb 23, 2026on EDGAR ↗
8-KFeb 3, 2026on EDGAR ↗
8-KDec 18, 2025on EDGAR ↗
8-KNov 10, 2025on EDGAR ↗
10-QNov 10, 2025on EDGAR ↗
8-KOct 27, 2025on EDGAR ↗
8-KOct 14, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Dec 31, 2025 · 10-K

Total Assets$1.96Bsource ↗
Stockholders’ Equity$1.69Bsource ↗
Cash & Equivalents$382.5Msource ↗
Long-Term Debt—source ↗

Income Statement

10-K (annual) · period ended Dec 31, 2025

Revenue$18.8Msource ↗
Net Income-$684.6Msource ↗
Operating Income-$745.9Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$559.2Msource ↗

Per Share & Cash Flow

10-K (annual) · period ended Dec 31, 2025

EPS (diluted)$-4.97source ↗
EPS (basic)$-4.97source ↗
Shares Outstanding155.1Msource ↗
Cash from Operations-$650.4Msource ↗
Cash from Financing$851.0Msource ↗
Cash from Investing-$38.0Msource ↗

Restatement history

Point-in-time

No material restatements detected across 180 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches RNAM’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/RNAM

MCP tool: get_sec_fundamentals ticker=RNAM

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/RNAM/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=RNAM as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/RNAM/history

MCP tool: get_fundamentals_history ticker=RNAM

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/RNAM

MCP tool: get_financial_health ticker=RNAM

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.